MarketInOut Stock Screener Log In | Sign Up

Viridian Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/20/2026
Viridian Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,437.41 mln
Float107 mln
Earnings Date03/11/2027

Piotroski F-Score

2 / 9
Weak

Beneish M-Score

-3.62
Highly reliable

1-Year Forecast

42.50
Exceptional upside

Relative Strength

95 / 100
Top performer

Debt / Equity

0.42
Low leverage

Pre-Tax Margin

-1,724%
Severely loss-making

Business Description

Viridian Therapeutics is a biopharmaceutical company focused on developing medicines for rare and serious conditions, with a particular emphasis on thyroid eye disease and Graves' disease. The company is advancing several drug candidates that work by blocking specific proteins involved in these conditions, including treatments given by injection under the skin as well as through a vein. Founded in 2010 and based in Waltham, Massachusetts, the company rebranded from Miragen Therapeutics in 2021.

Key Fundamentals

EPS-3.85
ROE-73.07
RPS0.25
ROIC-1,197
ROA-51.64
Interest Cover-16.95
EBITDA, mln-428
EV / EBITDA-6.13
EV / EBIT-6.12
Revenue, mln26.31
EV / Revenue99.81

Quote Details

Last 29.96
Change -1.48 (-4.71%)
Open 31.12
Volume 1,746,851
Turnover 52,335,656
Average Volume 2,892,761

Financial Ratios

Pre-Tax Profit Margin-1,724
Leverage Ratio1.77
Current Ratio14.46
Price / Book6.74
Price / Tangible Book6.87
Debt / Equity0.42
Price / Sales123

Financial Strength

Altman Z-Score1.81
Piotroski F-Score 2 / 9
Beneish M-Score-3.62
1-Year Target Price42.50
Short Ratio8.24
Short % of Float15.56

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -2.95% 70 / 100   
1 Month 31.29% 98 / 100   
2 Months 29.75% 98 / 100   
6 Months 73.78% 98 / 100   
1 Year 4.46% 65 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog